BreakThrough Digest - cancer,  medical information

BreakThrough Digest offers current medical news and health articles on medical breakthroughs, medical research and health information on clinical trials, cancer, Alzheimer's, stem-cell research, heart disease, diabetes and more.



HOME

RECENT HEADLINES

NEW RESEARCH

CLINICIAL TRIALS

COMMENTARY

FDA NEWS DIGEST

ADVERTISE

RESOURCES

Quick Links to:

  - Medical Journals
  - Government Health Sites
  - Pharmaceutical Companies
  - Archives
  - A Challenge for Health IT
  - Mobile Edition

Advertisers...

Neprinol
- exclusive distributors of pharmaceutical-grade products including neprinol, syntol, and devacor

Chelation - cardio renew is 100% pure edta providing cardiovascular cleansing by oral chelation.

 Bipolar Disorder & Research in the News

Treatment for Binge Eating Disorder - Psych Centra
Cognitive-behavioral therapy includes standard elements of behavioral treatment with a focus on identifying ... evidence that this anticonvulsant which is also used (off-label) in bipolar disorder helps control ...

EU Sanctions Merck & Co.'s Sublingual Bipolar Disorder Drug Sycrest - Genetic Engineering News
... for treating moderate to severe manic episodes in adult patients with bipolar I disorder. Sycrest was first approved in the U.S. in 2009, where it is marketed as Saphris® for the treatment of schizophrenia and ...

90.3 WCPN ideastream®: Kay Redfield Jamison: Living with Bipolar Disorder - WCPN
Imagine being bipolar since the age of 17 but avoiding treatment for years despite a nearly successful suicide attempt and relationships shattered beyond repair. Then imagine becoming a professor of psychiatry, an ...

European Commission approves MSD's MAA for SYCREST in manic episodes associated ... - News-Medical.Net
... approved the Marketing Authorization Application (MAA) for SYCREST ® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today's ...

Bipolar Disorder, My Ass - DAILY KOS
doctors who diagnose every moody patient they see as bipolar typically send the patient home with a prescription but rarely recommend a treatment – psychotherapy - which may have the potential to turn a patient’s ...

Forest Laboratories, Gedeon say bipolar depression drug fails to meet goal in ... - Washington Examiner
NEW YORK — Forest Laboratories Inc. and Gedeon Richter PLC said Monday their potential bipolar depression treatment cariprazine did non meet key goals in a midstage study. The study was designed to be exploratory and ...

European Commission Issues Positive Decision for Approval of Seroquel XR as an ... - WebWire
33 countries for bipolar maintenance, 6 countries for MDD, with US receiving approval of SEROQUEL XR for the adjunctive treatment of MDD in December 2009, and 3 countries for Generalised Anxiety Disorder (GAD).

Forest Laboratories, Gedeon say bipolar depression drug fails to meet goal in midstage study - Washington Examiner
NEW YORK — Forest Laboratories Inc. and Gedeon Richter PLC said Monday their potential bipolar depression treatment cariprazine did non meet key goals in a midstage study. The study was designed to be exploratory ...

MSD Receives European Approval of its Atypical Antipsychotic Medication SYCREST ... - PR Inside
... approved the Marketing Authorization Application (MAA) for SYCREST ® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today’s ...

Forest Laboratories, Inc. and Gedeon Richter Plc Announce Results from a Phase II Study of ... - PR Inside
investigational antipsychotic agent cariprazine for the treatment of bipolar depression. Cariprazine is currently undergoing Phase III trials for separate indications of schizophrenia and bipolar mania. A total of ...

 

Google

BreakThrough Digest
Copyright 2007 BreakThrough Digest
BreakThrough Digest subscribes to the eHealth Code of Ethics

 

medical new and medical breakthroughs health information and health articles about medicine on cancer, heart disease, diabetes and stem cell research

medrocket award

Trute